


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Joseph ROBERTS et al.  
Title: PEGYLATION OF THERAPEUTIC AGENTS  
Appl. No.: 09/972,245  
Filing Date: 10/09/2001  
Examiner: Unassigned  
Art Unit: 1645



1645  
#2  
6/11/02  
**RECEIVED**

JUN 07 2002

TECH CENTER 1600/2900

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

Pursuant to 37 C.F.R. §§ 1.97-98 and in accordance with the duty of disclosure under 37 C.F.R. §1.56, Applicant submits herewith the references listed on the attached Form SB-08 to the Examiner such that they may be considered and made of record in the above-identified application. A copy of each reference is enclosed.

**TIMING OF THE DISCLOSURE**

The listed documents are being submitted in compliance with 37 CFR §1.97(b), before the mailing date of the first Office Action on the merits.

If any fees are due upon the filing of this paper, the Commissioner for Patents is authorized to charge Deposit Account No. 19-0741.

Respectfully submitted,

Date 4 June 2002

By S. A. Bent

FOLEY & LARDNER  
Customer Number: 22428



22428

PATENT TRADEMARK OFFICE

Telephone: (202) 672-5404  
Facsimile: (202) 672-5399

Stephen A. Bent  
Attorney for Applicant  
Registration No. 29,768

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> Date Submitted: May 31, 2002 (use as many sheets as necessary)			<b>Complete if Known</b>		
Sheet <u>1</u> of <u>1</u>			Application Number	09/972,245	<div style="font-size: 2em; font-weight: bold; transform: rotate(-5deg);">RECEIVED</div> <div style="font-size: 1.2em; font-weight: bold; transform: rotate(-5deg);">JUN 07 2002</div> <div style="font-size: 1.2em; font-weight: bold; transform: rotate(-5deg);">TECH CENTER 1000/2900</div>
			Filing Date	10/09/2001	
			First Named Inventor	Joseph ROBERTS et al.	
			Group Art Unit	1645	
			Examiner Name	Unassigned	
			Attorney Docket Number	078728-0104	

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
	A1	5,122,614		ZALIPSKY	06/16/1992	
	A2	5,324,844		ZALIPSKY	06/28/1994	
	A3	5,612,460		ZALIPSKY	03/18/1997	
	A4	5,808,096		ZALIPSKY	09/15/1998	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>				

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	A5	ABUCHOWSKI et al.; "Alteration of Immunological Properties of Bovine Serum Albumin by Covalent Attachment of Polyethylene Glycol"; <i>The Journal of Biological Chemistry</i> ; Vol. 252, No. 11; pp. 3578-3581 (June 10, 1977)	
	A6	FRANCIS et al.; "Polyethylene Glycol Modification: Relevance of Improved Methodology to Tumour Targeting"; <i>Journal of Drug Targeting</i> ; Vol. 3; pp. 321-340 (1996)	
	A7	NUCCI et al.; "The therapeutic value of poly(ethylene glycol)-modified proteins"; <i>Advanced Drug Delivery Reviews</i> ; Vol. 6, pp. 133-151 (1990)	
	A8	ZALIPSKY; "Chemistry of polyethylene glycol conjugates with biologically active molecules"; <i>Advanced Drug Delivery Reviews</i> , Vol. 16; pp. 157-182 (1995)	

Examiner Signature	Date Considered	
--------------------	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2See attached Kinds of U.S. Patent Documents. 3Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.